Straumann® Roxolid®

More than solid – Roxolid®.
Reducing invasiveness.

Learn more
Contact us

Roxolid® is a high-performance alloy composed of 15% zirconium and 85% titanium, specifically designed by Straumann for use in implant dentistry. It features high tensile strength and excellent osseointegration capabilities, making it the material of choice for reduced invasiveness. Its properties allow for greater confidence and more treatment options through the placement of reduced diameter  (Straumann® Bone Level Tapered Implant Ø 2.9 mm) and shorter implants  (Straumann® Standard Plus 4 mm Short Implant), especially in cases where bone augmentation can be avoided. 

Strength

Higher mechanical strength compared to titanium.1
Preservation

Preserves bone and less invasive grafting procedures.2,3
Flexibility

More treatment options with smaller implants.
Osseointegration

The excellent osseointegration properties of Roxolid® implants in combination with our SLActive® surface9,10 leads to reduced treatment complexity.4-7,11,12
Patient acceptance

Less invasive treatment plans (= faster healing and less post-operative discomfort) can help to overcome many patient doubts.
Evidence

The successful use of Roxolid® has been documented in numerous clinical trials with up to 5-year follow-ups.8
Peace of Mind

Special conditions for Roxolid® implants: Straumann® Lifetime+ Guarantee.

Brochures and videos

Looking for additional information? You'll find them in the Resource Center.

YouTooth Articles

Contact us

Data usage agreement*

Read our privacy notice.

Please retype the code above

References

1 Bernhard N et al., (2009). Forum Implantologicum 5(30). 
2 Benic GI et al. ‘Titanium-zirconium narrow-diameter versus titanium regular-diameter implants for anterior and premolar single crowns: 1-year results of a randomized controlled clinical study.’ Journal of Clinical Periodontology 2013; [Epub ahead of print]
3 Freiberger P, Al-Nawas B. ‘Non-interventional Study on Success and Survival of TiZr Implants.’ EAO 2012 Copenhagen; 305 Posters – Implant Therapy Outcomes, Surgical Aspects. 
4 Al-Nawas B et al. (2012). Clin Implant Dent Relat Res 14(6):896-904.
5 Müller F et al. (2015). BMC Oral Health. 2015 Oct 12;15(1):123.
6 Quirynen M et al. (2015). Clin Oral Implants Res. Jul;26(7):831-40.
7 Altuna P et al., (2016). Int. J. Oral Maxillofac. Surg; in press. http://dx.doi.org/10.1016/j.ijom.2016.01.004
8 http://www.straumann.com/science-roxolid.html
9 Schwarz F et al., (2007); J Periodontol 78(11):2171-2184.
10 http://www.straumann.com/science-slactive.html
11 Gottlow J et al., (2012); Clin Implant Dent Relat Res 14 Suppl 1:e204-e212.
12 Wen B et al., (2014); Clinical Oral Implants Research. Jul;25(7):819-25.